Most recent articles by:

Jan Wehkamp

Jan Wehkamp, M.D. Ph.D., is Vice President, Gastroenterology Disease Area Leader at The Janssen Pharmaceutical Companies of Johnson & Johnson.
- Advertisement -

Janssen reports positive topline results for Tremfya in Crohn’s at week 48

The IL-23 Pathway and Its Pivotal Role in Inflammatory Bowel Disease Research The incidence of inflammatory bowel disease (IBD),...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

Amgen’s KRAS drug gets early FDA approval for lung cancer with specific mutation

On Friday, the United States FDA (Food and Drug Administration) has authorized a medication of Amgen Biopharmaceutical in patients with NSCLC
- Advertisement -